



CLAIMS

1. A method of treating Tourette Syndrome, comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a therapeutic agent or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent is a compound of Formula I:



2. The method of claim 1, wherein the subject has a total tic score of at least 22 on the Yale Global Tic Severity Scale at the start of treatment.

3. A method of treating Tourette Syndrome, comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a therapeutic agent or a pharmaceutically acceptable salt thereof, wherein the subject has a total tic score of at least 22 on the Yale Global Tic Severity Scale at the start of treatment and the therapeutic agent is a compound of Formula I:



4. The method of any one of claims 1-3, wherein the subject has previously been administered another therapy for Tourette Syndrome.

5. The method of claim 4, wherein the previous administration of another therapy for Tourette Syndrome is administration of pimozide, haloperidol, aripiprazole, methylphenidate, dextroamphetamine, lisdexamfetamine, atipamezole, efaroxan, or idazoxan.

6. The method of claim 5, wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, once daily.


7. The method of claim 5, wherein administering comprises administering orally the compound of Formula I, or a pharmaceutically acceptable salt thereof.

8. The method of claim 5, wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, as a unit dose.

9. The method of claim 1, wherein administering comprises administering the compound of Formula I in its free base form.

10. The method of claim 1, wherein administering comprises administering the compound of Formula I in the form of a pharmaceutically acceptable salt thereof.

11. A method of treating Tourette Syndrome, comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a phosphodiesterase 10 (PDE10) inhibitor or a pharmaceutically acceptable salt thereof, wherein the PDE10 inhibitor is a compound of Formula I:



12. The method of any one of claims 1-11, wherein the composition comprises the compound of Formula I, or a pharmaceutically acceptable salt thereof, as the sole active agent.

13. The method of any one of claims 1-11, wherein the composition comprises the compound of Formula I, or a pharmaceutically acceptable salt thereof, in combination with another active agent.

14. The method of claim 13, wherein the other active agent is olanzapine or risperidone.

15. The method of any one of claims 1-14, wherein the composition comprises inactive agents selected from the group consisting of mannitol, microcrystalline cellulose, sodium starch glycolate, sucrose monopalmitate, hydroxypropyl methylcellulose, colloidal silicon dioxide, and sodium stearyl fumarate.

16. The method of any one of claims 1-15, wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in a capsule.

17. The method of claim 16, wherein the capsule shell consists of gelatine, titanium dioxide, red iron oxide, and yellow iron oxide.

18. The method of claim 16, wherein the capsule comprises about 1 mg to about 10 mg of the compound of Formula I, or a pharmaceutically acceptable salt thereof.

19. The method of claim 18, wherein the capsule comprises about 2.5 mg to about 5 mg of the compound of Formula I, or a pharmaceutically acceptable salt thereof.

20. The method of any one of claims 1-19, wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount of about 2.5 mg to about 5 mg once daily.

21. The method of any one of claims 1-19, wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount of about 5 mg to about 15 mg once daily.

22. The method of claim 21, wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount of about 5 mg, about 7.5 mg, about 10 mg, about 12.5 mg, or about 15 mg once daily.

23. The method of any one of claims 1-22, wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an immediate release formulation.

24. The method of any one of claims 1-22, wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an extended release formulation.

25. The method of any one of claims 1-24, wherein administering maintains efficacy throughout the day.


26. The method of any one of claims 1-25, wherein the subject has attention-deficit hyperactivity disorder (ADHD).

27. The method of any one of claims 1-25, wherein the subject is free of ADHD.

28. The method of any one of claims 1-25, wherein the subject has obsessive-compulsive disorder (OCD).

29. The method of any one of claims 1-25, wherein the subject is free of OCD.


30. A method of treating Tourette Syndrome, comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a therapeutic agent or a pharmaceutically acceptable salt thereof, wherein the subject has a total tic score of at least 22 on the Yale Global Tic Severity Scale at the start of treatment and the therapeutic agent is a compound of Formula I:



(I),

wherein administering comprises administering the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount of about 5 mg to about 15 mg once daily.

31. A solid form of a compound of Formula I:



(I),


wherein the solid form is a crystalline solid of the free base of the compound of Formula I, and the crystalline solid has a melting point onset as determined by differential scanning calorimetry (DSC) of about 210-214 °C.

32. The solid form of claim 31, wherein the crystalline solid has an X-ray powder diffraction (XRPD) pattern as substantially shown in Figure 1.

33. The solid form of claim 31, wherein the crystalline solid has a DSC curve as substantially shown in Figure 2.

34. The solid form of any one of claims 31-33, wherein the crystalline solid is present in a capsule in an amount of about 1 mg to about 10 mg.

35. A method of treating Tourette Syndrome, comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a crystalline solid of the free base of the compound of Formula I:



(I),

wherein said crystalline solid has a melting point onset as determined by DSC of about 210-214 °C.

36. The method of claim 35, wherein the crystalline solid has an XRPD pattern as substantially as substantially shown in Figure 1.

37. The method of claim 35, wherein the crystalline solid has a DSC curve as substantially shown in Figure 2.